Karyopharm Therapeutics (KPTI) Inventory Average (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Inventory Average came in at $4.0 million in Q4 2025, down 14.95% YoY from $4.7 million in Q4 2024, and down 10.65% on a QoQ basis from $4.5 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Inventory Average (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Inventory Average data on file, last reported at $4.0 million in Q4 2025.
- Quarterly Inventory Average fell 14.95% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (down 14.95% YoY) and the FY2025 annual result came in at $4.4 million, up 12.79% from the prior year.
- Inventory Average fell to $4.0 million in Q4 2025, from $4.5 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $4.9 million in Q2 2025 to a low of $2.9 million in Q1 2021.
- A 5-year average of $3.9 million and a median of $4.0 million in 2021 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2021 — Inventory Average jumped 337.54% — and 2024, when it fell 27.81%.
- Tracing KPTI's Inventory Average over 5 years: stood at $4.0 million in 2021, then climbed by 5.27% to $4.2 million in 2022, then declined by 27.44% to $3.1 million in 2023, then surged by 53.07% to $4.7 million in 2024, then decreased by 14.95% to $4.0 million in 2025.
- The last three Inventory Average figures came in at $4.0 million (Q4 2025), $4.5 million (Q3 2025), and $4.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 213.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 707.10 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 90.57 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 137.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 196.36 Mn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | 4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 4.48 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 4.75 Mn |
| Dec 31, 2024 | 4.71 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | 2.91 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 30, 2023 | 3.39 Mn |
| Jun 30, 2023 | 3.75 Mn |
| Mar 31, 2023 | 4.03 Mn |
| Dec 31, 2022 | 4.24 Mn |
| Sep 30, 2022 | 3.86 Mn |
| Jun 30, 2022 | 3.67 Mn |
| Mar 31, 2022 | 3.99 Mn |
| Dec 31, 2021 | 4.02 Mn |
| Sep 30, 2021 | 3.92 Mn |
| Jun 30, 2021 | 3.51 Mn |